Study of BIIB092 in Participants With Progressive Supranuclear Palsy
Public ClinicalTrials.gov record NCT03068468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 \& 4 laboratory abnormalities. The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by the Clinical Global Impression of Change (CGI-C) at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) at Week 52 and to assess the impact of BIIB092 on quality of life, relative to placebo, as measured by change from baseline on the Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) at Week 52.
Study identification
- NCT ID
- NCT03068468
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 490 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 41 Years to 86 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2017 (Actual)
- Primary completion
- Sep 6, 2019 (Actual)
- Completion
- Feb 7, 2020 (Actual)
- Last update posted
- Dec 21, 2020
2017 – 2020
United States locations
- U.S. sites
- 33
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85013 | — |
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Sun City | Arizona | 85351 | — |
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | San Francisco | California | 94158 | — |
| Research Site | Boca Raton | Florida | 33486 | — |
| Research Site | Gainesville | Florida | 32607 | — |
| Research Site | Tampa | Florida | 33612-4742 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Name | Chicago | Illinois | 60612-3841 | — |
| Research Site | Chicago | Illinois | 60637-1447 | — |
| Research Site | Indianapolis | Indiana | 46202-2280 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | New Orleans | Louisiana | 70121-2429 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Burlington | Massachusetts | 01702 | — |
| Research Site | Farmington Hills | Michigan | 48334 | — |
| Research Site | Minneapolis | Minnesota | 55455-0341 | — |
| Research Site | New Brunswick | New Jersey | 08901 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | New York | New York | 100029 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | New York | New York | 10032-3725 | — |
| Research Site | Hershey | Pennsylvania | 17033 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Dallas | Texas | 75390-8869 | — |
| Research Site | Charlottesville | Virginia | 22908-0394 | — |
| Research Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03068468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2020 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03068468 live on ClinicalTrials.gov.